

31 Jan 2020 | News

QUOTED. 31 January 2020. Rafael Carbunaru.

by

Boston Scientific recently presented encouraging results of its COMBO study and discussed its partnership with IBM Health using digital health technologies and algorithms to gain an objective understanding of pain. See what Rafael Carbunaru, VP of R&D at Boston Scientific's neuromodulation division, said about it here.

"We believe that the typical measure of a 'sad face and happy face' doesn't really describe pain. Our vision is to develop algorithms that will make our therapies smarter and autonomous to adapt with the patient's needs." – Rafael Carbunaru, VP of R&D, Boston Scientific's neuromodulation division

- Find out more: [NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020](#)

[Click here](#) for a free trial of *Medtech Insight*